News
Stockhead on MSN6h
Clock ticking as Argenica nears phase II stroke trial readoutThe countdown is on with Argenica’s phase II trial results of lead drug ARG-007 in acute ischaemic stroke patients forecast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback